SCHEMBL8697148

SCHEMBL8697148

O=C(O)C(Cc1ccccc1)NC(F)P(=O)(O)O

nearest known ligand 0.53

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MME P08473 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.49
LAP3 P28838 3/20 0.49
ANPEP P15144 1/20 0.49
NPSR1 Q6W5P4 1/20 0.48
ACP3 P15309 1/20 0.47
PTPN1 P18031 1/20 0.47
NAALAD2 Q9Y3Q0 1/20 0.47
ECE1 P42892 1/20 0.46
CYP1A2 P05177 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9245828 0.84 MME (0.52) MMEL3MBTL1LAP3ANPEPNPSR1
SCHEMBL3506385 0.83 MME (0.58) MMEL3MBTL1NPSR1NAALAD2CYP1A2
SCHEMBL3506387 0.83 MME (0.58) MMEL3MBTL1NPSR1NAALAD2CYP1A2
SCHEMBL9242144 0.83 ECE1 (0.64) MMEL3MBTL1LAP3ANPEPECE1
SCHEMBL9715666 0.83 MME (0.51) MMEL3MBTL1LAP3ANPEPNPSR1
SCHEMBL9068541 0.82 MME (0.70) MMEL3MBTL1NPSR1NAALAD2CYP1A2
SCHEMBL7379335 0.82 MME (0.70) MMEL3MBTL1NPSR1NAALAD2CYP1A2
Ammonia Solution, Strong SCHEMBL2415760 0.81 MME (0.50) MMEL3MBTL1LAP3ANPEPNPSR1
SCHEMBL6770152 0.80 MME (0.55) MMEL3MBTL1NPSR1NAALAD2CYP1A2
SCHEMBL3090103 0.79 MME (0.48) MMEL3MBTL1LAP3ANPEPNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1994008600-A1 INHIBITION OF SIGNAL TRANSDUCTION MOLECULES JOSLIN DIABETES CENTER (US) 1994-04-28 WO claimed
US-20180264080-A1 TOPICAL APPLICATIONS OF Kv1.3 CHANNEL BLOCKING PEPTIDES TO TREAT SKIN INFLAMMATION KINETA ONE, LLC (US) 2018-09-20 US disclosed
US-9937230-B2 Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof KINETA ONE, LLC (US) 2018-04-10 US disclosed
US-20160338967-A1 SUSTAINED RELEASE DEPOT FORMULATIONS OF THERAPEUTIC PROTEINS, AND USES THEREOF KINETA ONE, LLC (US) 2016-11-24 US disclosed
EP-3086779-A2 SUSTAINED RELEASE DEPOT FORMULATIONS OF THERAPEUTIC PROTEINS, AND USES THEREOF Kineta One, LLC (US) 2016-11-02 EP disclosed
WO-2016112208-A2 TOPICAL APPLICATIONS OF KV1.3 CHANNEL BLOCKING PEPTIDES TO TREAT SKIN INFLAMMATION KINETA ONE, LLP (US) 2016-07-14 WO disclosed
US-20160151457-A1 OPHTHALMIC USES OF TOXIN-BASED THERAPEUTIC PEPTIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF KINETA ONE, LLC (US) 2016-06-02 US disclosed
EP-3024472-A2 OPHTHALMIC USES OF TOXIN-BASED THERAPEUTIC PEPTIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF Kineta One, LLC (US) 2016-06-01 EP disclosed
WO-2015100370-A2 SUSTAINED RELEASE DEPOT FORMULATIONS OF THERAPEUTIC PROTEINS, AND USES THEREOF KINETA ONE, LLC (US) 2015-07-02 WO disclosed
WO-2015013330-A2 OPHTHALMIC USES OF TOXIN-BASED THERAPEUTIC PEPTIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF KINETA ONE, LLC (US) 2015-01-29 WO disclosed
US-5801149-A PEPTIDS FOR INHIBITION OF PROTEINS JOSLIN D-ABETES CENTER, INC. (US) 1998-09-01 US disclosed
US-5475129-A Phosphonoalkyl phenylalanine compounds suitably protected for use in peptide synthesis THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1995-12-12 US disclosed
WO-1994008600-A1 INHIBITION OF SIGNAL TRANSDUCTION MOLECULES JOSLIN DIABETES CENTER (US) 1994-04-28 WO disclosed
WO-1993025561-A1 PHOSPHONOALKYL PHENYLALANINE COMPOUNDS SUITABLY PROTECTED FOR USE IN PEPTIDE SYNTHESIS THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1993-12-23 WO disclosed
US-5264607-A Process of making benzylic α,α-diflurophosphonates from benzylic α-ketophosphorates THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1993-11-23 US disclosed